TRENDING :  Market Movers  |  Top 50   SPY (0%)    BYND (0%)    CANF (0%)    ARQL (0%)    ARCI (0%)    FTNT (0%)    ELTK (0%)    MCHP (0%)    ONCS (0%)    VXX (0%)    KSS (0%)    IRBT (0%)    IP (0%)    INTC (0%)    GTN (0%)    GLW (0%)    DIS (0%)    DFRG (0%)    CMG (0%)    CGC (0%)    CCCL (0%)    BTCUSD (%)    BPY (0%)    BIOC (0%)    BIDU (0%)

 NVAX - Novavax

$6.25 [0][0%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $1.75
Low $1.75
Average $1.75
Current $6.25

CompanyAnalyst NamePT ActionActionRatingTargetDate
B. Riley FBRGeorge ZavoicoLowersMaintainsBuy$1.7503/04/19
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Better Buy: Novavax vs. Inovio Pharmaceuticals

It wasn t long ago that Novavax NASDAQ NVAX claimed a market cap more than twice the size of Inovio Pharmaceuticals NASDAQ INO Then Novavax announced in late February that its experimental respiratory syncytial 160 virus RSV vaccine ResVax failed to meet the

Are These 2 Beaten-Down Biotech Stocks Worth the Risk?

Catalyst Pharmaceuticals NASDAQ CPRX and Novavax NASDAQ NVAX have both had an absolutely terrible May so far Each company has shed a significant chunk of its value in just the first two weeks of the month Beaten down biopharma stocks though can recover in the blink of

Why Novavax Stock Is Fading Today

What happened Novavax NASDAQ NVAX a pre revenue vaccine company is posting yet another forgettable day As of 12 00 p m EDT the biotech s shares were down by 10 1 on above average volume What s sinking Novavax s ship today On April 1 the company announced

Is Novavax a Buy?

Novavax NASDAQ NVAX a developmental stage vaccine is navigating some rather turbulent waters these days After the company s phase 3 trial called Prepare which was designed to assess the respiratory syncytial virus vaccine RSV ResVax in infants via maternal

Novavax Inc (NVAX) Q1 2019 Earnings Call Transcript

Image source The Motley Fool Novavax Inc NASDAQ NVAX Q1 160 2019 Earnings Call May 02 2019 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator Good day ladies

Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates

Novavax NVAX came out with a quarterly loss of 0 11 per share versus the Zacks Consensus Estimate of a loss of 0 12 This compares to loss of 0 14 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise of 8 33

What's in the Cards for Novavax (NVAX) This Earnings Season?

In the absence of an approved product investors focus will be on the path forward for 160 Novavax Inc s NVAX two vaccine candidates when the company reports first quarter 2019 results The company s earnings missed the Zacks Consensus Estimate in one of the last four quarters and

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

For Immediate Release Chicago IL April 25 2019 Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec Every week Tracey will be joined by guests to discuss the hottest investing topics in stocks bonds and ETFs and how it impacts your life To listen to

Should You Buy Lottery Stocks?

1 00 Lottery Stocks What Are They and How To Find Them 6 30 Is Insider Buying A Good Sign To Start Investing 16 50 Sectors Primed For Lottery Stocks Retail and Pot Stocks 23 00 Are They Worth It 28 30 Episode Roundup NVAX PIR JCP CRON